DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Santen Pharmaceutical Co., Ltd.148 enrolled

Overview

Safety and IOP (intraocular pressure) lowering effect of DE-111 ophthalmic solution will be evaluated in open-angle glaucoma or ocular hypertension patients, in an open-label, multicenter study.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

148

Conditions

Open Angle Glaucoma or Ocular Hypertension

Interventions

DE-111 ophthalmic solutionDRUG

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with open angle glaucoma or ocular hypertension * Provided signed, written informed consent * 20 years of age and older * If a subject is a female of childbearing potential, she must utilize reliable contraceptive throughout the study, and must have a negative urine pregnancy test prior to enrollment into this study Exclusion Criteria: * Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception. * Presence of any abnormality or significant illness that could be expected to interfere with the study.

Locations (1)

Santen study sites

Osaka, Osaka, Japan

Outcomes

Primary Outcomes

Change From Baseline in IOP (Intraocular Pressure) at End of Study

Time frame: Treatment period: Week 0 (Baseline) and Week 52 (End of Study)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.